MapLight Therapeutics (Nasdaq: MPLT) announced that its Phase 2 IRIS study of ML-004 in autism spectrum disorder (ASD) did not ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE